Answers are grounded in this paper and cite their sources.
Radiation-induced intestinal injury (RIII) represents the primary dose-limiting toxicity of abdominopelvic radiotherapy. Its progression to chronic lesions marked by fibrosis and vascular sclerosis stems not merely from direct epithelial damage, but predominantly from dynamic remodeling of the intestinal immune microenvironment. This review systematically dissects stage-dependent immune cascades underlying RIII: damage-associated molecular patterns (DAMPs) from damaged epithelia trigger innate immune activation through TLR4/NLRP3/cGAS-STING axes; neutrophils and M1 macrophages fuel a self-perpetuating TNF-necroptosis-DAMP inflammatory loop; dendritic cell-mediated Th1/Th17 polarization may contribute to the transition to chronic injury; balanced macrophage repolarization, regulatory T cell (Treg) expansion, IL-22-dependent epithelial repair and commensal metabolites jointly determine inflammation resolution. Critically, we highlight three translational constraints: (i) limited extrapolability of single high-dose mouse data to clinical fractionated radiotherapy, (ii) phase-dependent opposing effects of therapeutic targets and (iii) shared core immune pathways creating a fundamental trade-off between intestinal radioprotection and radiotherapy-induced antitumor immunity. Accordingly, we advocate shifting the research focus in RIII from target screening to validating risk-stratified biomarkers, building tumor-bearing fractionated animal models with dual efficacy endpoints and developing spatial/temporal/target-selective decoupling regimens to separate normal gut protection from suppression of antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: